Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.61 |
| ▸ | ITGAV | P06756 | 8/20 | 0.61 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.61 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.61 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 7/20 | 0.51 |
| ▸ | MC5R | P33032 | 7/20 | 0.51 |
| ▸ | MC3R | P41968 | 7/20 | 0.51 |
| ▸ | MC1R | Q01726 | 7/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177741 | 1.00 | ITGB3 (0.61) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL279121 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL7744481 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL16188466 | 0.89 | ITGB3 (0.48) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL16177739 | 0.89 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL18970023 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14075705 | 0.88 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL22278847 | 0.88 | ITGB3 (0.52) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL7743533 | 0.87 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL19605481 | 0.87 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306377-A1 | METHODS FOR ENHANCING 5-AMINOLEVULINIC ACID-BASED MEDICAL IMAGING AND PHOTOTHERAPY | NANOCO TECHNOLOGIES LTD (GB) | 2020-10-01 | — | — | US | disclosed |
| US-9775803-B2 | Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-10-03 | — | — | US | disclosed |
| US-20170165198-A9 | LIPOSOME COMPRISING ELASTIN-LIKE POLYPEPTIDE AND TUMOR CELL TARGETING MATERIAL AND USE THEREOF | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20130102993-A1 | LIPOSOME COMPRISING ELASTIN-LIKE POLYPEPTIDE AND TUMOR CELL TARGETING MATERIAL AND USE THEREOF | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306377-A1 | METHODS FOR ENHANCING 5-AMINOLEVULINIC ACID-BASED MEDICAL IMAGING AND PHOTOTHERAPY | ALAD, AADAT, SLC1A5 | ITGB3 1797/4885ITGAV 238/4885ITGB1 2534/4885 |
| US-20130102993-A1 | LIPOSOME COMPRISING ELASTIN-LIKE POLYPEPTIDE AND TUMOR CELL TARGETING MATERIAL AND USE THEREOF | LNPEP, EBPL, LIPG | ITGB3 2998/4885ITGAV 2899/4885ITGB1 2810/4885 |
| US-20170165198-A9 | LIPOSOME COMPRISING ELASTIN-LIKE POLYPEPTIDE AND TUMOR CELL TARGETING MATERIAL AND USE THEREOF | LNPEP, EBPL, LIPG | ITGB3 2998/4885ITGAV 2899/4885ITGB1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.